Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour of variou...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cardiovasc Diabetol
Asıl Yazarlar: Schernthaner, Guntram, Shehadeh, Naim, Ametov, Alexander S., Bazarova, Anna V., Ebrahimi, Fahim, Fasching, Peter, Janež, Andrej, Kempler, Péter, Konrāde, Ilze, Lalić, Nebojša M., Mankovsky, Boris, Martinka, Emil, Rahelić, Dario, Serafinceanu, Cristian, Škrha, Jan, Tankova, Tsvetalina, Visockienė, Žydrūnė
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Commentary
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585305/
https://ncbi.nlm.nih.gov/pubmed/33097060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01154-w
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller